Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical …
Over the last 12 months, insiders at Rani Therapeutics Holdings, Inc. have bought $10.77M and sold $20.72M worth of Rani Therapeutics Holdings, Inc. stock.
On average, over the past 5 years, insiders at Rani Therapeutics Holdings, Inc. have bought $38.9M and sold $10.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: South Cone Investments Limited Partnership (10 percent owner) — $21.17M. BUTEL JEAN LUC (director) — $102,495. Imran Talat (Chief Executive Officer) — $86,525.
The last purchase of 10,000 shares for transaction amount of $22,700 was made by Imran Talat (Chief Executive Officer) on 2023‑12‑06.
2024-10-15 | Sale | 10 percent owner | 3.83M 8.9999% | $2.65 | $10.14M | +13.68% | ||
2023-12-06 | Chief Executive Officer | 10,000 0.0173% | $2.27 | $22,700 | +31.52% | |||
2023-12-04 | Chief Executive Officer | 5,000 0.0101% | $2.57 | $12,850 | +36.16% | |||
2023-11-29 | Chief Executive Officer | 20,000 0.0409% | $2.05 | $41,000 | +72.56% | |||
2023-11-24 | Sale | 10 percent owner | 5.27M 10.2552% | $2.01 | $10.58M | +67.01% | ||
2023-11-24 | 10 percent owner | 5.27M 10.2552% | $2.01 | $10.58M | +67.01% | |||
2023-11-17 | director | 50,500 0.0962% | $2.03 | $102,495 | +65.92% | |||
2023-11-16 | director | 500 0.0009% | $1.98 | $990 | +66.50% | |||
2023-11-07 | Chief Executive Officer | 5,000 0.0095% | $2.00 | $9,975 | +67.42% | |||
2023-05-12 | 10 percent owner | 2,645 0.0104% | $3.98 | $10,529 | -10.45% | |||
2023-05-11 | 10 percent owner | 2,610 0.0102% | $3.87 | $10,096 | -8.04% | |||
2023-05-08 | 10 percent owner | 4,420 0.0183% | $4.46 | $19,733 | -15.65% | |||
2023-05-03 | 10 percent owner | 2,040 0.0082% | $4.81 | $9,816 | -23.68% | |||
2023-04-28 | 10 percent owner | 2,173 0.0086% | $4.71 | $10,225 | -23.40% | |||
2023-04-25 | 10 percent owner | 4,423 0.0172% | $4.51 | $19,952 | -21.35% | |||
2023-04-24 | 10 percent owner | 4,280 0.0169% | $4.67 | $19,994 | -23.19% | |||
2023-04-21 | 10 percent owner | 4,100 0.0166% | $4.93 | $20,224 | -25.47% | |||
2023-04-20 | 10 percent owner | 1,850 0.0074% | $5.32 | $9,851 | -31.72% | |||
2023-04-18 | 10 percent owner | 1,850 0.0074% | $5.37 | $9,939 | -32.40% | |||
2023-04-14 | 10 percent owner | 1,901 0.0076% | $5.27 | $10,019 | -31.30% |
South Cone Investments Limited Partnership | 10 percent owner | 8302194 14.7186% | $2.50 | 64 | 1 | <0.0001% |
Imran Talat | Chief Executive Officer | 484455 0.8589% | $2.50 | 4 | 0 | |
BUTEL JEAN LUC | director | 50500 0.0895% | $2.50 | 1 | 0 | |
Quiroga Cortes Isidoro Alfonso | 10 percent owner | 8400 0.0149% | $2.50 | 5 | 1 | <0.0001% |
Nanavaty Maulik | director | 500 0.0009% | $2.50 | 1 | 0 |
The Vanguard Group | $2.13M | 1.36 | 685,303 | +2.54% | +$52,733.15 | <0.0001 | |
Nan Fung Group | $1.54M | 0.98 | 493,584 | 0% | +$0 | 1.67 | |
USAA | $1.5M | 0.96 | 481,300 | 0% | +$0 | 0.04 | |
Alphabet | $1.39M | 0.89 | 448,492 | 0% | +$0 | 0.01 | |
Stifel | $411,866.00 | 0.26 | 132,434 | +163.47% | +$255,540.16 | <0.0001 |